Piper Sandler Reiterates Overweight Rating on CRISPR Therapeutics (CRSP)
Bullish analyst stance and a large target-to-price gap support a positive view, though the reiteration itself is not a new upgrade.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst stance and a large target-to-price gap support a positive view, though the reiteration itself is not a new upgrade.
What happened, with direct paths to the underlying reporting
Piper Sandler reiterated an Overweight rating with a $110 target versus the posted price of $48.21, indicating substantial analyst-identified upside. This is an analyst view, not a guarantee of performance.
Target: $110
Posted price: $48.21
Analyst firm: Piper Sandler
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.